サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1290361

減量治療の世界市場：2023-2030

Global Weight Loss Therapeutics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
減量治療の世界市場：2023-2030
出版日: 2023年06月12日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

減量治療の世界市場は、2022年に27億9,800万米ドルに達し、2030年には最大149億7,810万米ドルに達することで有利な成長を遂げると予測されています。世界の減量治療市場は、予測期間中（2023-2030年）に24.3%のCAGRを示すと予測されています。

減量治療の市場範囲は、リラグルチド（Saxenda）、ナルトレキソン-ブプロピオン（Contrave）、フェンテルミン-トピラマート（Qsymia）、セマグルチド（Wegovy）、オルリスタット（Xenical、Alli）などの承認薬からなり、減量治療の市場シェアを高めてきました。

心血管障害の有病率の増加や新薬の研究開発の活発化が、減量治療の市場動向の需要を押し上げています。また、治療薬の進歩が進み、各国で医療認可が予定されているなどの要因により、減量治療の世界市場は拡大しており、減量治療市場の成長にも明るい見通しが立っています。

市場力学

慢性疾患の発生率の増加が、減量治療市場の成長を促進します

肥満は、精神的な健康状態の悪化や生活の質の低下につながるため、深刻な健康問題であると言えます。さらに、米国をはじめ世界中で、さまざまな種類のがん、心臓病、糖尿病、その他の主要な死因との関連も指摘されています。太っていると、高コレステロールや高血圧になりやすいです。この2つの疾患は、心臓病や脳卒中を発症するリスクを高める。

心臓病や脳卒中になる可能性は、少し体重を減らすことで減少させることができます。2型糖尿病患者の10人中8人は、肥満または過体重です。最終的に、高血糖は神経損傷、視力障害、腎臓病、心臓病、脳卒中などの他の健康問題を引き起こします。したがって、慢性疾患の増加は、減量治療市場を牽引しています。

食習慣とライフスタイルの変化が、メーカーに有利な機会をもたらす

技術の進歩や地球環境の変化がもたらすライフスタイルの変化により、減量治療の市場機会は拡大しています。また、糖尿病や肥満など、成人の間で多くの病気が蔓延していることも、減量治療市場を牽引する要因となっています。オーストラリアにおける肥満や過体重の割合が増加しているのは、世界の動向の結果です。

現在、男性の75％、女性の50％以上、子供やティーンエイジャーの約25％が太りすぎや肥満と考えられています。高エネルギー食が広く普及し、運動が不要になった現在、環境やライフスタイルの進化が大きな影響を与えていることは間違いありません。その結果、肥満とそれが引き起こす健康問題は、残念ながらオーストラリアの人々にとってあまりにも頻繁に起こるようになりました。

減量剤に関連する副作用が市場の成長を妨げる

最適な結果を得るために、減量剤は低カロリーの食事と医師の承認を得た運動プログラムとともに使用されます。しかし、食事療法と運動療法を継続しなければ、減量剤の使用を中止した後に、失った体重の一部が戻ってしまう可能性があります。

患者さんの中には、集中的な行動療法だけでは体重を減らすのに不十分だと感じる方もいます。また、体重に関連するその他の問題にも悩まされています。例えば、ホルモンの問題や、遺伝に起因する体重の問題などです。したがって、これらの上記の要因は、減量治療市場の成長を制限しています。

COVID-19の影響分析

COVID-19のパンデミックや世界各国での封鎖により、あらゆる業種の企業の財務状況が影響を受けています。そのため、COVID-19の公衆衛生上の緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーや研究者を支援し、試験参加者の安全を確保し、優良臨床試験（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な配慮を含むガイドラインを発表しました。

ロシア・ウクライナ紛争影響分析

ロシア・ウクライナ紛争は、この地域の主要な市場プレイヤーの数が少ないことから、世界の減量治療市場に与える影響は少ないと推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界の減量治療市場の成長にほとんど影響を及ぼさないと予想されます。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 承認済み医薬品別スニペット
  • 販売チャネル別
  • 地域別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 主要企業別臨床試験の活発化
      • 慢性疾患の発生率の増加
    • 抑制要因
      • 減量薬に関連する副作用
    • 機会
      • 食習慣とライフスタイルの変化
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 法規制の分析

第6章 COVID-19の分析

  • COVID-19の分析
    • COVID-19の前のシナリオ
    • COVID-19実施中のシナリオ
    • COVID-19後のシナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • サマリー

第7章 承認済み医薬品別

  • リラグルチド（Saxenda）
  • ナルトレキソン-ブプロピオン（Contrave）
  • フェンテルミン-トピラマート（Qsymia）
  • セマグルチド（Wegovy）
  • オルリスタット（Xenical、Alli）
  • セトメラノチド（Imcivree）

第8章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
      • その他アジア太平洋地域
  • 中東・アフリカ地域
    • 地域別の主なダイナミクス

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第11章 企業プロファイル

  • Novo Nordisk A/S
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展状況
  • Currax Pharmaceuticals LLC
  • Viking Therapeutics
  • Pfizer Inc.
  • Eli Lilly and Company
  • Altimmune
  • VIVUS LLC
  • Rhythm Pharmaceuticals
  • Amgen Inc.
  • Zealand Pharma A/S

第12章 付録

目次
Product Code: PH3616

Market Overview

The Global Weight Loss Therapeutics Market reached US$ 2,798.0 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 14,978.1 million by 2030. The global weight loss therapeutics market is expected to exhibit a CAGR of 24.3% during the forecast period (2023-2030).

The weight loss therapeutics market scope comprises approved drugs such as Liraglutide (Saxenda), Naltrexone-Bupropion (Contrave), Phentermine-Topiramate (Qsymia), Semaglutide (Wegovy) and Orlistat (Xenical, Alli) and others, which has increased the weight loss therapeutics market share.

The increasing prevalence of cardiovascular disorders and the growing research and development for novel drugs are driving up demand for weight loss therapeutics market trends. The global market for weight loss therapeutics is expanding as a result of factors including the increasing advances in therapeutics and their upcoming medical approvals across countries are also creating a positive outlook for the weight loss therapeutics market growth.

Market Dynamics

An Increase in the Incidence of Chronic Disorders Drives the Growth of the Weight Loss Therapeutics Market.

Because it is linked to poor mental wellness outcomes and a decreased quality of life, obesity is a severe health problem. Additionally, it has links to various types of cancer, heart disease, diabetes, and other major killers in the US and around the world. One is more prone to have high cholesterol and blood pressure if they are overweight. These two disorders increase the risk of developing heart disease or stroke.

The likelihood of having heart disease or a stroke can be decreased by losing a small amount of weight. Eight out of ten individuals with type 2 diabetes are obese or overweight. Eventually, high blood sugar causes other health issues such as nerve damage, vision problems, renal disease, heart disease, and stroke. Hence, the growing number of chronic disorders is driving the weight loss therapeutics market.

The Change in Food Habits and Lifestyle Creates Lucrative Opportunities for Manufacturers

Due to advancing technologies and changes in lifestyle brought on by a changing global environment, there is a growing market opportunity for weight loss therapies. Another factor driving the weight loss treatments market is the increasing prevalence of numerous illnesses among adults, such as diabetes and obesity. The rising rates of obesity and overweight in Australia are a result of a global trend.

Today, up to 75% of men, over 50% of women, and about 25% of kids and teenagers are considered overweight or obese. The environment and evolving lifestyles undoubtedly have a big impact now that high-energy meals are widely accessible and physical activity is no longer required. As an outcome, obesity and the health issues it causes have unfortunately become all too frequent in Australians.

Side Effects Associated with Weightloss Drugs Will Hamper the Growth of the Market

For optimal results, weight reduction drugs are used with a low-calorie diet and an exercise program that has been approved by a doctor. However, unless diet and exercise are continued, people may gain back part of the weight they lost after they stop using weight reduction medications.

Some patients find that intensive behavioral therapy is insufficient to help them lose weight. They also struggle with additional concerns that are related to their weight. These can include hormonal issues or weight issue that has genetic roots. Hence these above mentioned factors are limiting the weight loss therapeutics market's growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global weight loss therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global weight loss therapeutics market growth over the forecast period.

Segment Analysis

The global weight loss therapeutics market is segmented based on approved drugs, distribution channel and region.

Liraglutide (Saxenda) from the Approved Drugs Segment Accounts for Approximately 32.3% of the Market Share

Liraglutide is beneficial in causing and maintaining weight loss in a population of obese people, including those with type 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea. Liraglutide is a prescription anti-diabetic drug used for the treatment of obesity, type 2 diabetes, and persistent weight management. It is marketed under the brand name Victoza among others.

The U.S. FDA has approved an additional indication for Saxenda (liraglutide) in juvenile patients aged 12 and older who are obese, as determined by a specified body mass index (BMI), for the purpose of managing chronic weight. Saxenda is an adjuvant (extra therapy) to a low-calorie diet and increased physical exercise. Liraglutide helps patients with obesity lose weight and keep it off. Improved glycemic control is a special benefit provided by the medication.

Geographical Analysis

North America Accounted for Approximately 42.3% of the Market Share Owing to the Strong Presence of Major Players And Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for weight loss therapeutics for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of weight loss therapeutics, which has increased the demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for weight loss therapeutics.

Rising new product types or applications will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of diagnostic approaches for cancer or various other disorders, leading to the expansion of the market in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the weight loss therapeutics market include: F Hoffmann-la Roche Ltd, Currax Pharmaceuticals LLC, Viking Therapeutics, Pfizer Inc., Eli Lilly and Company, Altimmune, VIVUS LLC, Rhythm Pharmaceuticals, Amgen Inc. and Zealand Pharma A/S among others.

Why Purchase the Report?

  • To visualize the global weight loss therapeutics market segmentation based on approved drugs, distribution channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of weight loss therapeutics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global weight loss therapeutics market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Approved Drugs
  • 3.2. Snippet by Distribution Channel
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising Clinical Trials by Key Companies
      • 4.1.1.2. An Increase in the Incidence of Cronic Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with Weighloss Drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. The Change in Food Habits and Lifestyle
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Approved Drugs

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 7.1.2. Market Attractiveness Index, By Approved Drugs
  • 7.2. Liraglutide (Saxenda) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Naltrexone-bupropion (Contrave)
  • 7.4. Phentermine-topiramate (Qsymia)
  • 7.5. Semaglutide (Wegovy)
  • 7.6. Orlistat (Xenical, Alli)
  • 7.7. Setmelanotide (Imcivree)

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan

Australia

      • 9.5.5.4. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approved Drugs
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Novo Nordisk A/S *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Currax Pharmaceuticals LLC
  • 11.3. Viking Therapeutics
  • 11.4. Pfizer Inc.
  • 11.5. Eli Lilly and Company
  • 11.6. Altimmune
  • 11.7. VIVUS LLC
  • 11.8. Rhythm Pharmaceuticals
  • 11.9. Amgen Inc.
  • 11.10. Zealand Pharma A/S

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us